Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-Label, Dose Escalation Study to Assess the Safety and Efficacy of ISIS 301012 as Add-on Therapy in Homozygous Familial Hypercholesterolemia Subjects

NCT00280995 is registered in ClinicalTrials.gov with Kastle Therapeutics, LLC as lead sponsor.

NCT NCT00280995
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00280995 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-Label, Dose Escalation Study to Assess the Safety and Efficacy of ISIS 301012 as Add-on Therapy in Homozygous Familial Hypercholesterolemia Subjects
Lead sponsor
Kastle Therapeutics, LLC
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2006
Completion date
August 31, 2007
Enrollment
12 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

hypercholesterolemia, familial